科伦博泰生物-B(06990)： SKB103新药临床试验申请获国家药品监督管理局批准

智通财经03-24

智通财经APP讯，科伦博泰生物-B(06990)发布公告，本公司自主研发的新型靶向肿瘤相关抗原及免疫肿瘤学抗原(TAA–程序性细胞死亡配体1 (PD-L1))的双特异性抗体偶联药物 (bsADC) SKB103的新药临床试验(IND)申请已获国家药品监督管理局(NMPA) 药品审评中心(CDE)批准，用于治疗晚期实体瘤。这是本公司首个进入临床阶段的TAA-PD-L1 bsADC，也是继SKB571...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2621057905?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-24 16:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621057905","market":"us","top_or_hot":-1,"title":"科伦博泰生物-B(06990)： SKB103新药临床试验申请获国家药品监督管理局批准","media":"智通财经","content":"<div>\n<p>智通财经APP讯，科伦博泰生物-B(06990)发布公告，本公司自主研发的新型靶向肿瘤相关抗原及免疫肿瘤学抗原(TAA–程序性细胞死亡配体1 (PD-L1))的双特异性抗体偶联药物 (bsADC) SKB103的新药临床试验(IND)申请已获国家药品监督管理局(NMPA) 药品审评中心(CDE)批准，用于治疗晚期实体瘤。这是本公司首个进入临床阶段的TAA-PD-L1 bsADC，也是继SKB571...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1418024.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>科伦博泰生物-B(06990)： SKB103新药临床试验申请获国家药品监督管理局批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n科伦博泰生物-B(06990)： SKB103新药临床试验申请获国家药品监督管理局批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-24 16:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1418024.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，科伦博泰生物-B(06990)发布公告，本公司自主研发的新型靶向肿瘤相关抗原及免疫肿瘤学抗原(TAA–程序性细胞死亡配体1 (PD-L1))的双特异性抗体偶联药物 (bsADC) SKB103的新药临床试验(IND)申请已获国家药品监督管理局(NMPA) 药品审评中心(CDE)批准，用于治疗晚期实体瘤。这是本公司首个进入临床阶段的TAA-PD-L1 bsADC，也是继SKB571...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1418024.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1418024.html","article_id":"2621057905","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621057905","pubTimestamp":1774342081,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，科伦博泰生物-B 发布公告，本公司自主研发的新型靶向肿瘤相关抗原及免疫肿瘤学抗原的双特异性抗体偶联药物  SKB103的新药临床试验申请已获国家药品监督管理局 药品审评中心批准，用于治疗晚期实体瘤。这是本公司首个进入临床阶段的TAA-PD-L1 bsADC，也是继SKB571之后第二款进入临床阶段的用于肿瘤治疗的bsADC。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","06990":"科伦博泰生物","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC"},"translate_title":"Kelunbotai Bio-B (06990): SKB103 new drug clinical trial application approved by the National Medical Products Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1.5},"content_text":"智通财经APP讯，科伦博泰生物-B(06990)发布公告，本公司自主研发的新型靶向肿瘤相关抗原及免疫肿瘤学抗原(TAA–程序性细胞死亡配体1 (PD-L1))的双特异性抗体偶联药物 (bsADC) SKB103的新药临床试验(IND)申请已获国家药品监督管理局(NMPA) 药品审评中心(CDE)批准，用于治疗晚期实体瘤。这是本公司首个进入临床阶段的TAA-PD-L1 bsADC，也是继SKB571之后第二款进入临床阶段的用于肿瘤治疗的bsADC。作为ADC领域的行业领军者之一，本公司已建立起坚实的领先优势。目前，本公司自主研发的靶向人滋养细胞表面抗原2 (TROP2) ADC、靶向人类表皮生长因数受体2 (HER2) ADC均已获批上市，并展现出显着的临床疗效及差异化的竞争优势。与此同时，本公司着眼于肿瘤治疗的迭代升级，持续拓展创新布局，构建了涵盖放射性核素偶联药物(RDC)、bsADC 等前沿疗法的多元化管线矩阵，全力推动肿瘤现有治疗模式的突破与革新。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621057905","isCrawlerRequest":true}